Lack of pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects

Clinical Drug Investigation

Volumn 25, Issue 11, 2005, Pages 731-740

  Hassan Alin, M ^a   Naesdal, J ^a   Nilsson Pieschl, C ^a   Langstrom G ^a   Andersson, T ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ESOMEPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; HEMOCONCENTRATION; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 27644468341     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525110-00006     Document Type: Article

References (27)

1. Retail & Provider Perspective, National Prescription Audit, 1999-2000. Plymouth (PA): IMS Health, 2000
2. Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicentre study of hospitalization in rheumatoid arthritis: frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986; 29: 614-9
3. Hazleman BL. Incidence of gastropathy in destructive arthropathies. Scand J Rheumatol Suppl 1989; 78: 1-4
4. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastroduodenal injury. Am J Med 1998; 104 (3A): 23S-9S
5. Hirschowitz BI. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207-23
6. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990; 300: 278-84
7. Myerson RM. NSAID-associated gastroduodenal damage. J Pharm Med 1992; 2: 277-84
8. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 (1B): 31S-8S
9. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
10. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000; 284: 1247-55
11. Lenzer J. Pfizer is asked to suspend sales of painkiller [news item]. BMJ 2005; 330: 862
12. Young D. FDA ponders future of NSAIDS: Pfizer reluctantly withdraws Bextra. Am J Health Syst Pharm 2005; 62: 997-1000
13. US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex and Vioxx) and non-selective non-selectivel non-steroidal anti-inflammatory drugs (NSAIDs) [online]. Available from URL: http://www.fda.gov/cder/drg/infopage/cox2/ [Accessed 2005 Sep 5]
14. European Medicines Agency Post-authorisation of Medicines for Human Use. Questions and answers on celecoxib/COX-2 inhibitors [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/21074505en.pdf [Accessed 2005 Sep 5]
15. Kuehn BM. FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA 2005; 292: 1571-2
16. Young D. FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available. Am J Health Syst Pharm 2005; 62: 668-72
17. Murray S. Health Canada lukewarm on Vioxx panel findings [news item]. CMAJ 2005; 173: 350
18. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719-26
19. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with non- steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-34
20. Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432-4
21. Röhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40mg provides more effective acid control than standard doses of all other proton pump inhibitors [abstract]. Gut 2001; 49 Suppl. III: 2649
22. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347-56
23. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42: 545-56
24. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005, Aug 23; [Epub ahead of print]
25. Äbelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 96-972
26. Leemann T D, Transon C, Bonnabry P, et al. A major role of cytochrome P450 TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-95
27. Andersson T, Bredberg E, Lagerström PO, et al. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol 1998; 54: 399-404